Ada göre bir ilaç arayın

Apresoline ve Lupus eritematoz

Apresoline ilacının Lupus eritematoz hastalığı ile etkileşiminin güvenlik kontrolünün sonucu.

Kontrolün sonucu:

Apresoline <> Lupus eritematoz

Güncellik: 23.07.2019 Eleştirmen: MD PHD P.M. Shkutko, in

Drugs.com, Rxlist.com, Webmd.com, Medscape.com gibi yetkili kaynaklara dayalı kontrolün sonucunda bu ilacın bu komorbid hastalık ile etkileşmesi halinde zarar verebilen veya olumsuz etkisini artırabilen kontrendikasyonlar veya yan etkiler bulundu.

Tüketici:

Hayatım kullanımı sendrom, hastalık gibi alevlenme gibi, lupus ve lupus gelişimi ile ilişkili olmuştur. Tedavi sonrası lupus önceden kötüleşmesine yaşayan hastalarda kesilmelidir. Uzun süreli tedavi sırasında önce tam kan sayımı ve antinükleer antikor titreleri izlenmesi önerilir.

Kaynaklar

Shapiro KS, Pinn VW, Harrington JT, Levey AS "Immune complex glomerulonephritis in hydralazine-induced SLE." Am J Kidney Dis 3 (1984): 270-4
Pirmohamed M "Hydralazine-induced lupus: yet another autoantibody! triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine - comment." Hum Exp Toxicol 15 (1996): 361-2
Darwaza A, Lamey P-J, Connell JM "Hydrallazine-induced Sjogren's syndrome." Int J Oral Maxillofac Surg 17 (1988): 92-3
Carey RM, Coleman M, Feder A "Pericardial tamponade: a major presenting manifestation of hydralazine-induced lupus syndrome." Am J Med 54 (1973): 84-7
Freestone S, Ramsay LE "Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus." Br Med J 285 (1982): 1536-7
Sturman SG, Kumararatne D, Beevers DG "Fatal hydralazine-induced systemic lupus erythematosus." Lancet 12/03/88 (1988): 1304
Cush JJ, Goldings EA "Southwestern internal medicine conference: drug-induced lupus: clinical spectrum and pathogenesis." Am J Med Sci 290 (1985): 36-45
Weinstein J "Hypocomplementemia in hydralazine-associated systemic lupus erythematosus." Am J Med 65 (1978): 553-6
"Product Information. Apresoline (hydralazine)." Ciba Pharmaceuticals, Summit, NJ.
Innes A, Rennie JA, Cato GR "Drug-induced lupus caused by very-low-dose hydralazine." Br J Rheumatol 25 (1986): 225-31
Ihle BU, Whitworth JA, Dowling JP, Kincaid-Smith P "Hydralazine and lupus nephritis." Clin Nephrol 22 (1984): 230-8
Lunde PK, Frislid K, Hansteen V "Disease and acetylation polymorphism." Clin Pharmacokinet 2 (1977): 182-97
Fleming MG, Bergfeld WF, Tomecki KJ, et al "Bullous systemic lupus erythematosus." Int J Dermatol 28 (1989): 321-6
Blumenkrantz N, Christiansen AH, Ullman S, Asboe-Hansen G "Hydralazine-induced lupoid syndrome." Acta Med Scand 195 (1974): 443-9
Cameron HA, Ramsay LE "The lupus syndrome induced by hydralazine: a common complication with low dose treatment." Br Med J 289 (1984): 410-12
Macleod WN "Anaemia in the hydrallazine-induced lupus syndrome." Scott Med J 28 (1983): 181-2
Ramsey-Goldman R, Franz T, Solano FX, Medsger TA "Hydralazine induced lupus and sweet's syndrome: report and review of the literature." J Rheumatol 17 (1990): 682-4
Naparstek Y, Kopolovic J, Tur-Kaspa R, Rubinger D "Focal glumerulonephritis in the course of hydralazine-induced lupus syndrome." Arthritis Rheum 27 (1984): 822-5
Timbrell JA, Facchini V, Harland SJ, Mansilla-Tinoco R "Hydralazine-induced lupus: is there a toxic metabolic pathway?" Eur J Clin Pharmacol 27 (1984): 555-9
Hahn BH, Sharp GC, Irvin WS, et al "Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus." Ann Intern Med 76 (1972): 365-74
Perry HM "Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis." Am J Med 54 (1973): 58-72